EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET

Company Participants

George Elston - Chief Financial Officer

Nancy Lurker - President and Chief Executive Officer

Jay Duker - Chief Operating Officer

Scott Jones - Chief Commercial Officer

Conference Call Participants

Stacy Ku - Cowen

Eddie Hickman - Guggenheim Partners

Jennifer Kim - Cantor

Yale Jen - Laidlaw

Yi Chen - H.C. Wainwright

Operator

Good morning. My name is Michelle, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter 2022 Financial Results and Recent Corporate Developments Conference Call. There’ll be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company’s request.

I would now like to turn the call over to George Elston, Chief Financial Officer of EyePoint Pharmaceuticals.

George Elston

Thank you, and thank you all for joining us on today’s conference call to discuss EyePoint Pharmaceuticals second quarter 2022 financial results and recent corporate developments. With me today are; Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; and Scott Jones, Chief Commercial Officer.

Nancy will begin with a review of recent corporate updates. Dr. Duker will then discuss clinical plans for EYP-1901, and Scott will comment on our 20 – 2Q 2022 commercial performance. I will close with commentary on the second quarter 2022 financial results. We will then open up the call for your questions. Earlier this morning, we issued a press release detailing our financial results as well as commercial and operational developments. A copy of the release can be found on the Investor Relations tab on the company website, www.eyepointpharma.com.

Before we begin our formal comments, I’ll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments, and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements.

As a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC, and in other filings we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.